Amgen and kyowa kirin provide top-line results from rocatinlimab phase 3 ignite study in adults with moderate to severe atopic dermatitis

Ongoing studies are evaluating long-term maintenance and durability thousand oaks, calif. and tokyo , march 8, 2025 /prnewswire/ -- amgen (nasdaq:amgn) and kyowa kirin co., ltd.
TOP Ratings Summary
TOP Quant Ranking